The Association of Microglial Activation and Amyloid Reduction in APP+PS1 Transgenic Mice

Author(s): Dave Morgan, Paul Jantzen, Donna Wilcock, Giovanni DiCarlo, Ken Ugen, Marcia Gordon

Journal Name: Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents
Continued as Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry

Volume 3 , Issue 1 , 2003


One increasingly dominant hypothesis regarding the pathogenesis of Alzheimer dementia is the inflammation hypothesis. In brief, this hypothesis argues that at least some of the neurodegeneration found in this disease is secondary to excessive activation of microglia and astrocytes, resulting in secretion of pro-inflammatory mediators, activation of the complement cascade and degeneration of synapses and neurons. The APP+PS1 transgenic mouse is a model of Aβ amyloid deposition that results in a phenotype resembling some but not all aspects of Alzheimers. Our group has evaluated a number of manipulations designed to both exacerbate and ameliorate the microglial activation in this transgenic model, ranging from LPS injections, administration of anti-Aβ antibodies and treatment with antiinflammatory drugs. Contrary to our original predictions that microglial activation should exacerbate the Alzheimer phenotype in these mice, we find that treatments that cause microglial activation are associated with reduced amyloid loads. These data are discussed in the context of differences between the murine and human immune systems and qualitative differences in the Aβ deposits found in these mouse models compared to human specimens.

Keywords: microglial activation, amyloid reduction, transgenic mice, amyloid deposition

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [27 - 32]
Pages: 6
DOI: 10.2174/1568013033358680

Article Metrics

PDF: 8